|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1750 EUR | +1.16% |
|
-7.65% | +2.94% |
| 25-09-30 | Celyad Oncology to Sell Belgian Research Facility for EUR3 Million | MT |
| 25-09-29 | Celyad Oncology announces research facility divestiture | RE |
Company Valuation: Celyad Oncology SA
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 135.2 | 92.3 | 79.42 | 11.43 | 16.16 | 29.5 |
| Change | - | -31.75% | -13.96% | -85.6% | 41.33% | 82.56% |
| Enterprise Value (EV) 1 | 100.3 | 78.7 | 52.03 | -0.7575 | 10.21 | 26.2 |
| Change | - | -21.51% | -33.89% | -101.46% | 1,448.08% | 156.6% |
| P/E ratio | -4.24x | -5.36x | -2.07x | -0.28x | -1.19x | -5.06x |
| PBR | 2.96x | 2.98x | 1.82x | 2.65x | 2.56x | 57.7x |
| PEG | - | 0.1x | -0.1x | -0.04x | 0x | 0.1x |
| Capitalization / Revenue | 22,540x | 18,460x | - | - | 158x | 159x |
| EV / Revenue | 16,711x | 15,740x | - | - | 100x | 141x |
| EV / EBITDA | -3.48x | -3.07x | -1.95x | 0.04x | -1.13x | -4.61x |
| EV / EBIT | -3.4x | -3x | -1.91x | 0.04x | -1.07x | -4.46x |
| EV / FCF | -6.88x | -7.09x | -3.86x | 0.07x | -0.71x | -17.2x |
| FCF Yield | -14.5% | -14.1% | -25.9% | 1,398% | -142% | -5.83% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -2.286 | -1.234 | -1.699 | -1.812 | -0.3284 | -0.1406 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.006 | 0.005 | - | - | 0.102 | 0.186 |
| EBITDA 1 | -28.83 | -25.6 | -26.68 | -19.55 | -9.004 | -5.687 |
| EBIT 1 | -29.49 | -26.24 | -27.24 | -20.26 | -9.512 | -5.87 |
| Net income 1 | -28.63 | -17.2 | -26.51 | -40.94 | -8.448 | -5.824 |
| Net Debt 1 | -34.98 | -13.6 | -27.39 | -12.19 | -5.946 | -3.295 |
| Reference price 2 | 9.7000 | 6.6200 | 3.5150 | 0.5060 | 0.3900 | 0.7120 |
| Nbr of stocks (in thousands) | 13,942 | 13,942 | 22,594 | 22,594 | 41,429 | 41,429 |
| Announcement Date | 3/25/20 | 3/24/21 | 3/24/22 | 3/23/23 | 4/4/24 | 4/4/25 |
1EUR in Million2EUR
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 9.09M | |
| 38.88x | 5.65x | 18.93x | 0.88% | 48.93B | |
| 33.47x | 3.33x | 14.23x | -.--% | 40.48B | |
| 103.47x | 6.63x | 66.61x | -.--% | 37.42B | |
| 55.18x | 11.32x | 31.46x | 0.35% | 31.03B | |
| -21.53x | 6248.57x | -20.41x | -.--% | 23.25B | |
| 41.27x | 6.69x | 30.41x | -.--% | 17.21B | |
| Average | 41.79x | 1,047.03x | 23.54x | 0.2% | 28.33B | |
| Weighted average by Cap. | 45.64x | 738.28x | 25.31x | 0.27% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- CYAD Stock
- Valuation Celyad Oncology SA
Select your edition
All financial news and data tailored to specific country editions
